Patents by Inventor John J. O'Shea

John J. O'Shea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS
    Publication number: 20110177526
    Abstract: An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.
    Type: Application
    Filed: March 4, 2011
    Publication date: July 21, 2011
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT., OF HEALTH & HUMAN SERVICES
    Inventors: John J. O'Shea, Warren J. Leonard, James A. Johnston, Sarah M. Russell, Daniel W. McVicar, Masaru Kawamura
  • Janus family kinases and identification of immune modulators
    Patent number: 7902348
    Abstract: An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: March 8, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: John J. O'Shea, Warren J. Leonard, James A. Johnston, Sarah M. Russell, Daniel W. McVicar, Masaru Kawamura
  • JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS
    Publication number: 20090137787
    Abstract: An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.
    Type: Application
    Filed: January 15, 2009
    Publication date: May 28, 2009
    Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEA
    Inventors: John J. O'Shea, Warren J. Leonard, James A. Johnston, Sarah M. Russell, Daniel W. McVicar, Masaru Kawamura
  • Janus family kinases and identification of immune modulators
    Patent number: 7488808
    Abstract: An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: February 10, 2009
    Assignee: United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: John J. O'Shea, Warren J. Leonard, James A. Johnston, Sarah M. Russell, Daniel W. McVicar, Masaru Kawamura
  • Janus family kinases and identification of immune modulators
    Patent number: 7070972
    Abstract: An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: July 4, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: John J. O'Shea, Warren J. Leonard, James A. Johnston, Sarah M. Russell, Daniel W. McVicar, Masaru Kawamura
  • Evaluation and treatment of patients with progressive immunosuppression
    Patent number: 5583002
    Abstract: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels and T-lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, or a protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.
    Type: Grant
    Filed: December 11, 1992
    Date of Patent: December 10, 1996
    Assignees: Regents of the University of Minnesota, The United States of America as represented by the Department of Health and Human Services
    Inventors: Augusto C. Ochoa, Hiromoto Mizuguchi, John J. O'Shea, Dan L. Longo, Cynthia M. Loeffler
  • Evaluation and treatment of patients with progessive immunosuppression
    Patent number: 5296353
    Abstract: A method of determining the level of immunosuppression in a mammal involves determining the level of expression of at least one selected TCR subunit protein, or protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in healthy individuals. The method is useful to identify patients having T lymphocytes capable of activation for autologous adoptive immunotherapy and for identifying agents which cause or reverse immunosuppression.
    Type: Grant
    Filed: April 6, 1992
    Date of Patent: March 22, 1994
    Assignees: The United States of America as represented by the Department of Health and Human Services, Regents of the University of Minnesota
    Inventors: Augusto C. Ochoa, Hiromoto Mizoguchi, John J. O'Shea, Dan L. Longo, Cynthia M. Loeffler